Verified Market Research® is pleased to announce the release of its latest market research report on the “Non-Invasive Prenatal Testing Market – Trends, Opportunities, and Forecasts”, offering ...

The following segment was excerpted from the Alger Mid Cap Focus Fund Q4 2025 Commentary.Class A shares of the Alger Mid Cap ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 ...

Class A shares of the Alger Spectra Fund underperformed the Russell 3000 Growth Index during the fourth quarter of 2025. Read ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s expanded 21-gene Fetal Focus single gene ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an ...

Natera NTRA recently announced a collaboration with NVIDIA NVDA to speed up the development of its multimodal AI foundation ...

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, ...

Quantification of CMV DNA during NIPS is accurate and sensitive for CMV viral load; stratifies risk for primary maternal infection, cCMV.

A new study indicates that noninvasive prenatal screening (NIPS) performed using a low-cost form of whole genome sequencing can detect pregnant mothers at risk for transmitting cytomegalovirus (CMV) - ...

The FDA has published new guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs), in the latest stage of an ongoing effort to reduce ...